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Original Article
According to data from the Ministry of Health in Brazil,
in 1998, cardiovascular disease accounted for more than
250,000 deaths, corresponding to 32% of all causes of death
in our country. Of the cardiovascular causes, cerebral stroke
was first, followed by myocardial ischemic disease 1.
The contribution of traditional risk factors for corona-
ry artery disease in the general population emerged from the
studies in the city of Framingham 2. The recent guidelines of
the National Cholesterol Education Program in the United
States (Adult Treatment Panel III) 3 recognize other markers
of coronary risk, classified as risk factors related to lifestyle
(obesity, physical inactivity, and atherogenic diet) and
emerging risk factors [lipoprotein (a), homocysteine, mar-
kers of thrombosis and inflammation, altered fasting glyce-
mia, and evidence of subclinical atherosclerosis] 3. The
metabolic syndrome, whose substrate is insulin resistance,
has been proposed to explain lipid, hemostatic, and inflam-
matory abnormalities, predisposing individuals to early
coronary artery disease (CAD) 4,5.
Apolipoprotein AI, the major protein component of
HDL, is an in vivo activator of lecithin-cholesterol acyltrans-
ferase (LCAT) and plays a crucial role in reverse cholesterol
transport 6. Apolipoprotein CIII is a component of the parti-
cles rich in triglycerides and of HDL and influences the regu-
lation of plasma concentrations of triglycerides. Apolipo-
protein CIII was shown in vivo to inhibit the lipoprotein and
hepatic lipases, reducing hydrolysis of triglycerides,
making the recognition of the remnant particles by hepatic
receptors difficult 7. The genes that regulate the expression
of apolipoproteins AI and CIII are very closely located in a
gene complex in the long arm of human chromosome 11 8,9.
Polymorphisms in nontranslated regions of the APO AI
gene with substitutions G/A (-75 pb) and C/T (+83 pb) (M1
and M2 alleles) and in exon 4 of the APO CIII gene (3238 C/
G) have been reported in association with alterations in
Objective – To assess the risk factors, lipid and apoli-
poprotein profile, hemostasis variables, and polymor-
phisms of the apolipoprotein AI-CIII gene in early corona-
ry artery disease (CAD).
Methods – Case-control study with 112 patients in
each group controlled by sex and age. After clinical eva-
luation and nutritional instruction, blood samples were
collected for biochemical assays and genetic study.
Results – Familial history of early CAD (64 vs 39%),
arterial hypertension (69 vs 36%), diabetes mellitus (25 vs
3%), and previous smoking (71 vs 46%) were more preva-
lent in the case group (p<0.001). Hypertension and diabe-
tes were independent risk factors. Early CAD was characte-
rized by higher serum levels of total cholesterol (235 ± 6 vs
209 ± 4 mg/dL), of LDL-c (154 ± 5 vs 135 ± 4 mg/dL), trigly-
cerides (205 ± 12 vs 143 ± 9 mg/dL), and apolipoprotein B
(129 ± 3 vs 105 ± 3 mg/dL), and lower serum levels of HDL-c
(40 ± 1 vs 46 ± 1 mg/dL) and apolipoprotein AI (134 ± 2 vs
146 ± 2mg/dL) [p<0.01], in addition to an elevation in
fibrinogen and D-dimer (p<0.02). The simultaneous pre-
sence of the rare alleles of the APO AI-CIII genes in early
CAD are associated with hypertriglyceridemia (p=0.03).
Conclusion – Of the classical risk factors, hyperten-
sion and diabetes mellitus were independently associated
with early CAD. In addition to an unfavorable lipid profile,
an increase in the thrombotic risk was identified in this
population. An additive effect of the APO AI-CIII genes was
observed in triglyceride levels.
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polymorphisms.
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(Thrombotimer). Type-1 plasminogen activator inhibitor,
von Willebrand factor, and D-dimer were assessed with the
immunoenzymatic assay technique (American Diagnosti-
ca). Because the patients in the case group were in seconda-
ry prevention of coronary atherosclerotic disease, the ana-
lyses were performed under antiplatelet therapy (acetyl
salicylic acid in 103 patients); the patients receiving oral an-
ticoagulants were excluded from coagulation studies. No
patient in the control group was taking antiplatelet agents or
anticoagulants.
Total genomic DNA was extracted from leukocytes
with an extraction set (GFXTM Genomic Blood Purification
Kit, Amersham Bioscience). Amplification of the genes of
interest occurred with polymerase chain reaction (PCR), in a
thermocycler (Peltier Effect Cycling, MJ Research) program-
med for 5 minutes at 94oC, 30 cycles, with 1 minute at 94oC,
1.5 minutes at 60oC, and 1.5 minutes at 72oC, followed by a
final extension of 10 minutes at 72oC.
The primers (Gibco) used were:
APO AI: sense 5’-AGGGACAGAG CTGATCCTTGA
ACTCTTAAG-3’, anti-sense 5’ TTAGGGGCACCTAGCCC
TCAGGAAGAGAGCA-3’;
APO CIII: sense 5’-GGTGACCGATGGCTTCAGTT-
3’, anti-sense 5’-CAGAAGGTGGATAGAGCGCT-3’
The purified products of PCR were digested with Msp I
(for APO AI) and Sst I (for APO CIII) restriction endonuclea-
ses and the appropriate buffers (Invitrogen) for 3 hours at
37oC. The digestion products were separated by 1.5% aga-
rose gel electrophoresis (45 minutes, 5 V/cm), stained with
ethidium bromide, and visualized under ultraviolet light. The
Msp I restriction endonuclease cleaves DNA in the 5’C-
CGG3’ sequence. In the APO AI gene (433 pb), it causes the
cleavage of a normally existing site, determining 2 alleles, M1
(l77 bp) and M2 (255 bp). It also determines the polymorphic
sites with the following bands: l77 (M1 --), 177, 110, 67 (M1 +-)
and 110, 67 pb (M1++) for the M1 allele; and 255 (M2), 255, 207,
48 (M1+-) and 207 and 48 pb (M2++) for the M2 allele.
The Sst I restriction endonuclease recognizes A in the
5’GAGCT-C3’ sequence, causing cleavage of the APO CIII
gene into 2 fragments with 265 and 163 pb bands.
The rare alleles are characterized by the absence (APO
AI) and presence (APO CIII) of restriction sites of the
enzymes.
The chi-square test was used to analyze the categori-
cal variables, to test the deviations of the Hardy-Weinberg
genotypic distribution, and also to compare the genotypic
frequencies between cases and controls. The continuous
variables were expressed as mean ± EPM. The means were
tested with the nonpaired Student t test for equal or une-
qual variances as appropriate. The lipid distribution accor-
ding to the genotypes, and the number of rare alleles were
compared by the Student t test and analysis of variance
(ANOVA), respectively. Multiple logistic regression was
used to assess the associations among parameters and
coronary artery disease. P values < 0.05 were considered
significant.
serum lipids, with CAD 10-13, and with familial combined
hyperlipidemia 14.
The present study aimed at identifying cardiovascular
risk factors and markers in a population with early CAD.
Methods
A case-control study was carried out in consecutive
patients, 112 with early coronary artery disease (men
< 45, women < 55 years) and 112 with no manifestation of
atherosclerosis, controlled by sex and age. All patients
were consecutively selected from the cardiology outpatient
care clinic at the Federal University of São Paulo (UNIFESP).
The criteria for CAD included a history of myocardial
infarction, stable or unstable angina, and surgical or percu-
taneous revascularization.
The controls comprised the spouses, neighbors, and
people from the same workplace of the patients, with the
same sociocultural conditions, in whom the clinical history,
the objective search for signals of CAD, and the electrocar-
diographic examination did not suggest the presence of that
disease.
The following patients were excluded from the study:
those with acute coronary syndromes, those who had
undergone myocardial revascularization surgery, those
who had undergone percutaneous intervention during the
first 3 months of those events, and those with renal (serum
creatinine > 2.0 mg/dL) or hepatic failure, uncontrolled
hypothyroidism, or neoplasias.
The protocol was approved by the Committee on
Ethics in Research of the UNIFESP. After obtaining infor-
med consent, clinical and nutritional assessments were per-
formed. The lipid-lowering drugs were withdrawn (statins
for 4 weeks and fibrates for 8 weeks), and the patients were
advised to follow the American Heart Association diet
(AHA step I). After this period of time, blood samples were
collected after a fasting period of 12 hours for general
biochemistry and other specific assays.
The risk factors were identified according to the
recommendations of the II Brazilian Guidelines on Dyslipi-
demias 15. In regard of tobacco consume, patients smoking
any number of cigarettes regularly for a period longer than
six months were considered previous smokers; those
smoking any number of cigarettes within one  month prior to
the interview were considered current smokers; these
guidelines were recently validated by the National Choles-
terol Education Program of the USA (NCEP III) 3.
A complete lipid profile was performed by an automa-
ted enzymatic method, and LDL–c was estimated by using
the Friedewald formula 16. The apolipoproteins were deter-
mined with nephelometry [AI, B, and Lp (a), Beckman, and
apolipoprotein E, Behring].
Fibrinogen was estimated according to the Clauss me-
thod 17, and factor VII was estimated by the addition of a
plasma deficient in factor VII and thromboplastin (Sim-
plastin Excel), both using the photomechanical method
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Results
The baseline characteristics of the patients  are shown
in table I. No differences were seen regarding sex and age
distribution of patients among groups. One hundred and
nine patients underwent coronary angiography and had a
wide range of coronary obstructions. Two-or three-vessel
involvement was the predominant distribution pattern of
coronary lesions in the case group patients (tab I).
Familial history of early coronary artery disease (64%
vs 39%; p=0.0002), arterial hypertension (69% vs 36%;
p<0.0001), diabetes mellitus (25% vs 3%; p<0.0001), and
previous smoking (71% vs 46%; p<0.0001) were highly pre-
valent in the group with early CAD as compared with those
in the control group. Prevalence of current smoking, howe-
ver, did not differ (26% vs 25%) between the groups. Body
mass index (BMI) was similar in both groups (27.5 ± 4.8 vs
26.7 ± 4.6), and most patients were obese or overweight
(65% vs 62%, p>0.05).
Total cholesterol (235 ± 6 vs 209 ± 4 mg/dL; p=0.0002),
LDL-c (154 ± 5 vs 135 ± 4 mg/dL; p=0.002), and triglycerides
(205 ± 12 vs 143 ± 9 mg/dL; p=0.0001) were higher in patients
with early CAD, whose levels of HDL-c (40 ± 1 vs 46 ± 1 mg/
dL; p=0.0006) were lower. Lower levels of apolipoprotein AI
(134 ± 2 vs 146 ± 2 mg/dL; p=0.0003) and higher levels of
apolipoprotein B (129 ± 3 vs 105 ± 3 mg/dL; p<0.0001) were
observed in early CAD. No difference was observed in the
levels of apolipoprotein E (3.7 ± 0.4 vs 3.3 ± 0.3 mg/dL) and
Lp(a) (43 ± 4 vs 33 ± 5 mg/dL). Figures 1 and 2 depict the
lipid and apolipoprotein distribution according to quartiles.
The TC/HDL (6.4 ± 0.2 vs 5.0 ± 0.2, p<0.0001) and LDL/
HDL (4.1 ± 0.2 vs 3.1 ± 0.1, p=0.0001) ratios were greater in
the case group.
Platelet aggregation to ADP 3µM was lower in the
group with CAD (62 ± 2 vs 71 ± 3%; p=0.02). Higher levels of
fibrinogen (351 ± 13 vs 308 ± 9 mg/dL; p=0.006) and D-dimer
(43 ± 9 vs 20 ± 3 ng/mL; p=0.01) were observed in early
CAD; PAI-1 (38 ± 1 vs 37 ± 1 ng/mL), factor VII (116 ± 5 vs 107
± 4%), and von Willebrand factor (81 ± 2 vs 79 ± 2%) did not
differ. Figure 3 depicts the distribution of markers of
hemostasis per quartiles.
DNA for APO AI genotyping was obtained in 104 pa-
tients in each group, and for APO CIII in 107 cases and 104
controls. The genotypic frequencies observed and ex-
pected for the APO AI and APO CIII genes were in Hardy-
Weinberg equilibrium. Table II shows the distribution of
APO AI (M1 and M2) and APO CIII genotypes  in case and
control groups, no differences being observed between
them.
Apolipoprotein AI, HDL-c, and triglycerides did not
differ between APO AI and APO CIII genotypes, even
when the 2 groups were considered as a whole, or when
each group was considered separately. When the effect of
multiple rare alleles (M1 - /M2 - /S2) was considered,
hypertriglyceridemia was observed in the presence of 2 rare
alleles in the group with early CAD (TG with 2 alleles > TG
with 0 allele, p=0.03, ANOVA) (tab III).
Multiple logistic regression showed that only arterial
hypertension and diabetes mellitus were independently
associated with early CAD (tab IV).
Discussion
The aim of this study was to identify in patients with
early CAD the classical risk factors and some of the new
risk markers, including apolipoproteins and hemostasis
variables, in addition to polymorphisms of the APO AI-CIII
genes. These genetic markers were chosen because they
participate in lipoprotein metabolism, affecting the removal
of remnant particles, and also reverse cholesterol transport.
In addition, those markers are related to the metabolic
syndrome and to a form of dyslipidemia commonly found in
individuals surviving an early infarction (familial combined
hyperlipidemia) 18.
As a case-control study, the choice of each group is
critical to the correct interpretation of the data. Therefore,
constitution of early CAD group was based on the presence
of coronary atherosclerosis, while the control group was
characterized by the complete absence of symptoms and
coronary history, as well as normal electrocardiographic
findings. Although subclinical atherosclerosis cannot be
ruled out, the absence of manifest atherosclerosis, in a
population controlled by age and sex, was considered
appropriate, because autopsy studies have reported the
gradual development of initial lesions throughout life 19,20.
Therefore, sophisticated methods, such as ultrasonogra-
phy, angioresonance, and ultrafast tomography have been
questioned in regard to their capacity for foretelling
coronary events 21, 22.
The relevant findings in early CAD were as follows: a
high prevalence of classic risk factors, with hypertension
and diabetes being independently associated, and an un-
Table I - Characteristics of the individuals in the case and control
groups according to age, sex, and clinical presentation
Group
Case Control P
n (%) n (%)
Age (median) 46 45 ns
Men 65 (58) 66 (59) ns
Women 47 (42) 46 (41) ns
Clinical presentation:
AMI 85 (76) -
Unstable angina 12 (11) -
Stable angina 15 (13) -
Coronary angiography:
One-vessel 39 (35) -
Two-vessel 35 (31) -
Three-vessel 26 (23) -
No obstructive lesion 9 (8) -
Not performed 3 (3) 112 (100)
Stroke 13 (2) -
Peripheral vascular disease 20 (18) -
Data express the number of patients and %. AMI- acute myocardial infarction;
ns- nonsignificant.
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favorable lipid profile characterized by elevation in total
cholesterol, LDL-c, and triglycerides, and reduction in
HDL–c. Among the new risk markers, higher levels of
apolipoprotein B and lower levels of apolipoprotein AI
were observed in early CAD. In addition, higher levels of
fibrinogen and D-dimer in a chronic and stable phase of
coronary artery disease suggest an increased thrombotic
risk, even under of antiplatelet therapy. Although the geno-
typic distribution between the groups did not differ, an asso-
ciation between the number of rare alleles and high triglyce-
rides was observed in early CAD.
In the PROCAM study, 48.4% of the men aged 45 to 65
years who developed CAD were hypertensive 23, while in the
MRFIT study, in a 12-year follow-up, 49% of the deaths cau-
sed by CAD, in the same age group, were related to hyper-
tension 24. Likewise, the prevalence of diabetes mellitus
observed in early CAD (25%) was 8 times greater than that
observed in controls, greater than that observed in the
individuals who developed coronary artery disease in the
PROCAM study 23, and much greater than its prevalence in
the general Brazilian population, around 7.5% 25. A positive
familial history of early CAD suggests a strong inherited or
environmental component. In the PROCAM study, family
history characterized a high-risk group 23, and, recently,
NCEP III began to consider it as a major risk factor 3. The risk
of CAD among smokers in the PROCAM study was more
than twice that of nonsmokers, while the risk of an ex-smoker
was only mildly increased as compared with that of nonsmo-
kers 23. The high prevalence of smoking at the time of the
initial manifestation of coronary artery disease contributed
to the formation and growth of the atherosclerotic plaque in
oxidative processes, and prothrombotic and proinflamma-
tory phenomena 26, 27.
The high prevalence of overweight and obesity in
both groups suggests the presence of a metabolic compo-
nent in this population. Exposure of the individuals to a simi-
lar BMI promoted great differences, both in the occurrence
of diabetes mellitus and in dyslipidemia. Therefore, comple-
te expression of the metabolic syndrome or of the coronary
risk seems to depend on other conditions, possibly genetic,
Fig. 1 – Lipid distribution according to quartiles. Box-plots contain the 1st and 3rd quartiles, the median, and the whiskers represent the lowest and the greatest values. * p<0.001
vs control (paired Student t test).
case control case control
case controlcase control
Total Cholesterol
(mg/dL)
Triglycerides
mg/dL
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to express the typical lipid phenotype. The aggregation of
risk factors found in our study was another determinant of
the early occurrence of the disease. The association of arteri-
al hypertension and diabetes, an elevation in TG, and a
reduction in HDL-c favored the hypothesis that metabolic
syndrome participates in the development of early CAD.
Abnormal levels of serum lipids and apolipoproteins
characterizes the patients with early CAD, who had a type of
dyslipidemia with an increase in atherogenic lipoproteins
and in apolipoprotein B, lower levels of HDL-c and apo AI. A
study assessing cohorts of young individuals showed a
strong association between serum cholesterol, coronary ar-
tery disease, and cardiovascular death 28, greater than that
observed for middle-aged men with the same cholesterole-
mia. The HDL-c levels in early CAD were similar to those ob-
served in the PROCAM study (40 vs 46 mg/dL) 23, and
those patients would not be identified by the reference
values used until the publication of the 2001 NCEP III
guidelines 3 as well as those from the Brazilian Society of
Cardiology. In our study, hypertriglyceridemia alone was
not observed in the group with early CAD, but in associa-
tion with low HDL–c or high LDL–c, or both, representing
an additional risk to those patients.
Several studies have related the higher levels of apoli-
poprotein B and the lower levels of apolipoprotein AI to the
early occurrence of CAD, to the presence of recurring
events, and to thrombotic processes 29,30. Total apolipopro-
tein E reflects both the atherogenic particles containing Apo
E and the Apo E of HDL, and their levels may not have diffe-
red among groups because the higher content of Apo E in
Apo E in triglyceride-rich particles, and lower in HDL may
have masked differences in patients with early CAD 31. The
Lp(a) levels are genetically determined and are under ethnic
influences 32. Both groups showed increased Lp(a) levels,
which could be related to the ethnic heterogeneity in our
community.
In vitro platelet aggregation was significantly attenua-
ted in early CAD due to the chronic use of antiplatelet
agents. However, other markers of hemostasis, such as fibri-
nogen and D-dimer, were elevated despite the use of those
agents in a chronic and stable phase of the disease, sug-
gesting increased thrombotic risk, which may reflect a con-
tinuous process of thrombosis and fibrinolysis, occurring
with no clinical manifestation and under insufficient protec-
tion of  platelet aggregation inhibitors. Several prospective
and transversal studies related high levels of fibrinogen to
Fig. 2 – Distribution of the apolipoproteins according to the quartiles. Box-plots contain the 1st and 3rd quartiles, the median, and the whiskers represent the lowest and the
greatest values. * p<0.001 vs control (paired Student t test).
Apolipoprotein A1
(mg/dL)
Apolipoprotein B
(mg/dL)
Lipoprotein (a)
(mg/dL)
Apolipoprotein E
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CAD, and a meta-analysis reassured these findings 33.
Recently, other authors reported an independent asso-
ciation between CAD and fibrinogen, present even after
correction for covariates34. Fibrinogen influences platelet
aggregation, interacts with a binding site of plasminogen,
and participates in thrombus formation. Fibrinogen has a
positive association with age, obesity, smoking, diabetes,
and LDL-c levels, and an inverse association with HDL-c
levels 35. Fibrinogen is an acute-phase protein, but it may
also reflect the chronic process of atherosclerosis, because
it is incorporated into the plaque, stimulating the pro-
liferation of smooth muscle cells and contributing to the
development of coronary artery disease. Our findings in
Fig. 3 – Distribution of the markers of hemostasis according to the quartiles. ADP = adenosine diphosphate; vWF = von Willebrand factor; F VII = fator VII; PAI-1= type 1 plasminogen
activator inhibitor. Box-plots contain the 1st and 3rd quartiles, the median, and the whiskers represent the lowest and the greatest values. * p<0.03 vs control (paired Student t test).
ADP
(%)
Fibrinogen
(mg/dL)
D-dimer
(ng/mL)
PAI-1
(ng/mL)
FVII (%) VWF (%)
case        control case       control case                        control
case                        controlcase                        control
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Table II - Distribution of the APO AI and APO CIII genotypes
between the case and control groups
Group
Case Control P
n % n %
M1 ++ 89 (85) 85 (82) ns
M1 + - 13 (13) 18 (17) ns
M1 - - 2 (2) 1 (1) ns
M2 ++ 65 (63) 71 (68) ns
M2 + - 37 (35) 31 (30) ns
M2 - - 2 (2) 2 (2) ns
S1S1 81 (76) 71 (68) ns
S1S2 23 (21) 32 (31) ns
S2S2 3 (3) 1 (1) ns
Data express the number of patients and %; case = control, p>0.05, chi-square
test; ns- nonsignificant.
 Table III - HDL-c, Apo AI, and triglyceride levels according to the
number of rare alleles in early CAD
Number of rare alleles
2  n 1  n 0  n P
HDL – c 38± 3.7 14 40±1.6 52 39±1.6 37 Ns
Apo AI 137±8.5 14 137±3.8 50 129±3.6 37 Ns
TG 290± 40 38 202± 18 52 190± 16 14 0.03*
Data represent mean ± EPM and the number of individuals. Values in mg/
dL. TG2 > TG0 alleles, *p<0.05, ANOVA. Apo- apolipoprotein; ns- non-
significant.
Table IV - Interaction of the risk factors and markers in CAD
Logistic regression
Odds ratio CI P
Hypertension 3.68 2.14 – 6.32 0.000002*
Diabetes mellitus 2.00 1.11 – 3.59 0.02*
Previous smoking 0.69 0.41 – 1.17 0.16
+ FH 1.01 0.93 – 1.09 0.86
TC 1.04 0.73 – 1.50 0.81
HDL-c 0.99 0.97 – 1.01 0.29
TG 1.01 0.92 – 1.11 0.81
Apo AI 1.48 0.88 – 2.50 0.14
Apo B 1.02 0.99 – 1.04 0.22
CI- confidence interval. *P<0.05. + FH = familial history of early CAD; TG-
triglycerides; Apo- apolipoprotein.
regard of fibrinogen elevation may be attributed to the lipid
profile of these patients, to the increased BMI, and to dia-
betes mellitus, all increasing the thrombotic risk.
Elevated levels of D-dimer in the chronic phase of
CAD were observed in our patients, and similar findings
were reported by Salomaa et al 36. After a myocardial infarc-
tion, the increase in D-dimer was associated with the exten-
sion of atherosclerosis, with ventricular dysfunction, and
with the presence of ventricular aneurysms, acting like a he-
modynamic marker 37 and a marker of recurrent events 38.
Because D-dimer levels increase with age, and considering
the relative stability of the patients in our study, elevated D-
dimer levels should not be expected and reflect the presence
of fibrinolysis, even with no clinical evidence of thrombo-
sis. Autopsy data from patients who died due to acute myo-
cardial infarction showed rupture of plaques and silent
thrombosis in unrelated arteries 39. These plaques are more
frequent in diabetic and hypertensive patients. As a whole,
our findings suggest a dynamic and silent process of
thrombosis and fibrinolysis.
PAI-1 levels were elevated in both groups and did not
identify early CAD. Those levels may be explained by the
influence of smoking, increased body mass index, ethnic
differences, and the high prevalence of metabolic syndrome.
Similar levels of factor VII and von Willebrand factor in
our patients  may be related to ethnic background the first
case, and to the chronic and stable phase of the disease, in
both 40.
Genotypic frequencies of  M1 and M2 alleles did not
differ between the case and control groups, and they were
similar to those reported in a meta-analysis 41 of 14 studies
including patients with CAD, healthy individuals, and
mixed groups. No difference was observed in regard to the
levels of HDL-c and apolipoprotein AI between the geno-
types. However, a trend towards lower levels of Apo AI was
observed in M1- carriers (p=0.07). In early CAD, Reguero et
al 42 reported a high frequency of the M1- allele in unstable
angina, with no difference in apolipoprotein AI levels. The
M1- allele was also associated with combined familial
hyperlipidemia 43. The same study showed lower HDL-c levels
in M2- carriers in early CAD.
No difference was found in the genotypic frequencies
of the APO CIII gene among groups, as well as  no associa-
tion between genotypes and triglyceride levels, although
these associations have been reported in another study 44.
Our results regarding triglycerides may have been masked
because these patients were under nutrition counselling,
and different responses to diet modification are observed
among genotypes. In addition, the analysis of triglyceride
levels during a fasting period may not allow the assessment
of the metabolic role of triglycerides for CAD.
On the other hand, hypertriglyceridemia was obser-
ved in the presence of 2 rare alleles only in patients with
early CAD. This finding suggests an additive effect of the
alleles of the APO AI and APO CIII genes as a result of the
effect of apolipoproteins AI and CIII in the metabolism of
the triglyceride-rich lipoproteins and in HDL. Although
these polymorphisms are located in an untranslated region,
they interfere with the efficiency of the transcription of the
APO AI and APO CIII genes, affecting the stability of
mRNA.
In conclusion, patients with early coronary artery
disease were characterized by the presence of classic risk
factors, an unfavorable lipid profile, and an increase in
thrombotic risk even in the chronic phase of the disease.
Arterial hypertension and diabetes mellitus were indepen-
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dently associated with early CAD. The rare alleles of the
APO AI and APO CIII genes had an additive effect on trigly-
ceride levels only in patients with early CAD, suggesting
gene–gene and gene–environment interactions. Early
identification of patients with metabolic syndrome seems
crucial for preventing premature coronary artery disease.
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